Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 20/20 | 0.40 |
| ▸ | DNER | Q8NFT8 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | TSPO | P30536 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19973043 | 0.88 | RECQL (0.35) | BRD4DNER | |
| SCHEMBL19973044 | 0.88 | RECQL (0.35) | BRD4DNER | |
| SCHEMBL23321070 | 0.88 | GABRA1 (0.44) | BRD4 | |
| SCHEMBL25514093 | 0.88 | GABRA1 (0.44) | BRD4 | |
| SCHEMBL23810818 | 0.86 | CHRM1 (0.43) | BRD4DNERADORA3TSPO | |
| SCHEMBL23348743 | 0.86 | CHRM1 (0.43) | BRD4DNERADORA3TSPO | |
| SCHEMBL31498747 | 0.84 | BRD4 (0.45) | BRD4DNERADORA3TSPO | |
| SCHEMBL18979672 | 0.83 | BRD4 (0.46) | BRD4DNERADORA3TSPO | |
| SCHEMBL30013402 | 0.83 | BRD4 (0.38) | BRD4DNERADORA3TSPO | |
| SCHEMBL17165522 | 0.83 | BRD4 (0.46) | BRD4DNERADORA3TSPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112543764-B | Amide compound with BET proteolytic induction effect and medical application thereof | 田边三菱制药株式会社 | 2024-05-10 | — | — | CN | disclosed |
| US-11542273-B2 | Amide compound having bet proteolysis-inducing action and medicinal application thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-01-03 | — | — | US | disclosed |
| WO-2022221786-A2 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THAT MODULATE BRD4 | Plexium, Inc. (US) | 2022-10-20 | — | — | WO | disclosed |
| US-20210284654-A1 | AMIDE COMPOUND HAVING BET PROTEOLYSIS-INDUCING ACTION AND MEDICINAL APPLICATION THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2021-09-16 | — | — | US | disclosed |
| EP-3512853-B1 | FUSED 1,4-DIAZEPINES AS BET PROTEIN DEGRADERS | UNIV MICHIGAN REGENTS (US) | 2020-12-23 | — | — | EP | disclosed |
| WO-2019055444-A1 | BET BROMODOMAIN PROTEIN DEGRADERS WITH CLEAVABLE LINKERS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2019-03-21 | — | — | WO | disclosed |
| WO-2018144789-A1 | FUSED 1,4-DIAZEPINES AS BET BROMODOMAIN INHIBITORS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2018-08-09 | — | — | WO | disclosed |
| WO-2018052949-A1 | FUSED 1,4-DIAZEPINES AS BET PROTEIN DEGRADERS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2018-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11542273-B2 | Amide compound having bet proteolysis-inducing action and medicinal application thereof | BET1, BRD4, PHKB | BRD4 2/4885DNER 780/4885ADORA3 4629/4885 |
| US-20210284654-A1 | AMIDE COMPOUND HAVING BET PROTEOLYSIS-INDUCING ACTION AND MEDICINAL APPLICATION THEREOF | BET1, BRD4, PHKB | BRD4 2/4885DNER 690/4885ADORA3 4656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.